CONCORD
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Concord Drugs Says S. Nagi Reddy Re-Appointed As Chairman & MD
Concord Drugs Temporarily Holds Fundraising And Capital Increase Proposal
June 27 (Reuters) - Concord Drugs Ltd CNCO.BO:
CONCORD DRUGS LTD - TEMPORARILY HOLDS FUNDRAISING AND CAPITAL INCREASE PROPOSAL
Source text: ID:nBSE1Cr0k1
Further company coverage: CNCO.BO
June 27 (Reuters) - Concord Drugs Ltd CNCO.BO:
CONCORD DRUGS LTD - TEMPORARILY HOLDS FUNDRAISING AND CAPITAL INCREASE PROPOSAL
Source text: ID:nBSE1Cr0k1
Further company coverage: CNCO.BO
Concord Drugs Puts Fundraising And Capital Increase On Hold
March 17 (Reuters) - Concord Drugs Ltd CNCO.BO:
CONCORD DRUGS LTD - PUTS FUNDRAISING AND CAPITAL INCREASE ON HOLD
Source text: ID:nBSE3kVTZJ
Further company coverage: CNCO.BO
March 17 (Reuters) - Concord Drugs Ltd CNCO.BO:
CONCORD DRUGS LTD - PUTS FUNDRAISING AND CAPITAL INCREASE ON HOLD
Source text: ID:nBSE3kVTZJ
Further company coverage: CNCO.BO
Concord Drugs To Consider Fund Raising
March 4 (Reuters) - Concord Drugs Ltd CNCO.BO:
TO CONSIDER FUND RAISING
Source text: ID:nBSE50XYTc
Further company coverage: CNCO.BO
March 4 (Reuters) - Concord Drugs Ltd CNCO.BO:
TO CONSIDER FUND RAISING
Source text: ID:nBSE50XYTc
Further company coverage: CNCO.BO
Events:
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Concord Drugs do?
Concord Drugs Limited, founded in 1995, is a leading pharmaceutical company in India. Specializing in generics, branded, and specialty pharmaceuticals, Concord is known for its diverse product portfolio of over 200 prescription and over-the-counter products.
Who are the competitors of Concord Drugs?
Concord Drugs major competitors are Denis Chem Lab, Godavari Drugs, Krebs Biochem.&Inds, Makers Laboratories, Mercury Laboratories, Bal Pharma, Lactose India. Market Cap of Concord Drugs is ₹94 Crs. While the median market cap of its peers are ₹94 Crs.
Is Concord Drugs financially stable compared to its competitors?
Concord Drugs seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Concord Drugs pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Concord Drugs latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Concord Drugs allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Concord Drugs balance sheet?
Balance sheet of Concord Drugs is strong. But short term working capital might become an issue for this company.
Is the profitablity of Concord Drugs improving?
The profit is oscillating. The profit of Concord Drugs is ₹0.57 Crs for TTM, ₹0.34 Crs for Mar 2025 and ₹0.47 Crs for Mar 2024.
Is the debt of Concord Drugs increasing or decreasing?
The net debt of Concord Drugs is decreasing. Latest net debt of Concord Drugs is ₹16.73 Crs as of Sep-25. This is less than Mar-25 when it was ₹18.91 Crs.
Is Concord Drugs stock expensive?
Yes, Concord Drugs is expensive. Latest PE of Concord Drugs is 165, while 3 year average PE is 48.48. Also latest EV/EBITDA of Concord Drugs is 26.97 while 3yr average is 13.12.
Has the share price of Concord Drugs grown faster than its competition?
Concord Drugs has given better returns compared to its competitors. Concord Drugs has grown at ~2.63% over the last 10yrs while peers have grown at a median rate of 2.16%
Is the promoter bullish about Concord Drugs?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Concord Drugs is 54.39% and last quarter promoter holding is 54.39%.
Are mutual funds buying/selling Concord Drugs?
There is Insufficient data to gauge this.
